Incorporated in 2004 in Mauritius, the CIDP head office occupies today an area of 2000 m² with specially designed facilities for research and clinical activities as well as for all support functions (Data Management, Biostatistics, administrative areas…). We are located in the first regional Hub dedicated to biotechnologies: BioPark Mauritius. The Mauritian population accounts for 1.2 Million inhabitants of multiethnic origins, with changes in lifestyle and rapid development, non-communicable and chronic diseases have been on the rise and account today for 80% of the diseases noted in the country. Some specific pathologies have a very high prevalence such as Diabetes Mellitus with over 120 000 diabetics on the island (23% of the population) and coronary heart disease (responsible for 30% of deaths). Cancer is also on the rise with an average increase of 40% in newly reported cases since 2005. Skin diseases are very present such as psoriasis, atopic dermatitis, acne, vitiligo and other skin pigmentation disorders. CIDP Mauritius has a staff of 60 members, all multilingual and with a very high level of qualification.


In 2010, CIDP incorporated its first subsidiary in Bucharest. Today, CIDP Romania occupies a building of 875 m² in the heart of the capital. Romania has a Population of 19 million of which more than 2 million are located in Bucharest. The higher education level is aligned with the European higher education area. Romania is a member of the European Union, which implies no regulations regarding the import and export of medicines or biological samples within the European Union countries. The most common causes of death are cardiovascular diseases. Cancer is the second leading cause of death. Lung Cancer is common among men and breast and cervical cancer among women. It is estimated that a fifth of the total population of Romania suffers from a communicable or chronic disease. Skin disorders, such as acne, psoriasis, dermatitis are also quite common among the population. The CIDP team in Romania comprises 40 extremely well-trained members, who are proactive and very dedicated to their field of activity.


CIDP opened in 2012 an affiliate in Rio-de-Janeiro. With a population of 6.4 Million (and a metropolitan area estimated at 16 Million), this city is the 2nd largest and richest city in Brazil, it‘s also the 3rd largest metropolitan area and agglomeration in South America and accounts for the 30th richest city in the world with a GDP of R$ 201,9 billion in 2010. The Brazilian population is of multicultural and ethnic origins: Caucasian, Africans and Mixed-race. Diabetes is among the main pathologies that can be found in Brazil, causing 31,000 deaths a year or 3.4% of total mortality; cardiovascular diseases are also widely spread, the leading causes of mortality being due to ischemic heart diseases (25% of total deaths) and cerebrovascular diseases (34%). However, cancer remained the leading cause for mortality. Dermatological disorders like acne, Dermatitis, eczema, psoriasis, vitiligo,... are common within the population.


CIDP India was open in 2010 in New Delhi and our center occupies today an area of 450 m2. This vibrant city of 23 Million inhabitants (India’s urban population soaring from 340 million in 2008 to an estimated 590 million in 2030) has a very big medical infrastructure with over 600,000 English-speaking physicians and more than 100,000 specialists with at least 2500 investigators among them. 9 of the top 15 global pharmaceutical and biotech companies have set up captive clinical research centres in India. CIDP India is located in a friendly clinical environment in the heart of the capital and close to major hospitals facilities. India has 16% of the global population and 20% of the global diseases burden. Cardiovascular diseases such as angina or congestive heart failure are rising in this country, as well as Diabetes. There are 61 million diabetics and this number is expected to rise further in the coming years. Also, India presents a large variety of dermatoses such as: psoriasis (6% prevalence rate), melasma (30%), vitiligo (3%) and acne (12%). With a team of 30 professionals highly qualified in clinical research, CIDP India is able to answer to all your specific requests for clinical studies.


In order to provide the most complete services to its clients, CIDP has opened a subsidiary in Asia. With excellent infrastructure, high level of Human Resources qualifications and a very good legal framework, Singapore offers an excellent environment for CIDP to develop a high performing centre for clinical research... With a population of 5.4 million inhabitant and very high living the health condition of the Singaporeans is consider as good by international standards. Leading causes of morbidity and mortality are major non-communicable diseases such as cancer, coronary heart diseases, strokes, pneumonia, diabetes, hypertension and injuries. In 2009, cancer, ischaemic heart disease and pneumonia together accounted for approximately 60% of the total causes of death. These diseases share many common risk factors such as smoking, obesity, physical inactivity and alcohol consumption. Located in Biopolis, the heart of research and development for Sciences, this latest CIDP subsidiary of 300 m2 is fully operational since October 5th 2015. It’s location in the newest hub’s infrastructure of BioPolis (Nucleos), is close to major universities and hospitals and thus allow a rapid and efficient recruitment of patients/volunteers.